Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S. Recht M, et al. Among authors: hay c. Haemophilia. 2009 Jul;15(4):869-80. doi: 10.1111/j.1365-2516.2009.02027.x. Epub 2009 Apr 9. Haemophilia. 2009. PMID: 19473411
Inhibitors in haemophilia: clinical aspects.
Dimichele D, Rivard G, Hay C, Antunes S. Dimichele D, et al. Among authors: hay c. Haemophilia. 2004 Oct;10 Suppl 4:140-5. doi: 10.1111/j.1365-2516.2004.00993.x. Haemophilia. 2004. PMID: 15479387 Review.
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group; Collins PW. Björkman S, et al. J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x. J Thromb Haemost. 2010. PMID: 20398185 Free PMC article.
European retrospective study of real-life haemophilia treatment.
Berntorp E, Dolan G, Hay C, Linari S, Santagostino E, Tosetto A, Castaman G, Álvarez-Román MT, Parra Lopez R, Oldenburg J, Albert T, Scholz U, Holmström M, Schved JF, Trossaërt M, Hermans C, Boban A, Ludlam C, Lethagen S. Berntorp E, et al. Among authors: hay c. Haemophilia. 2017 Jan;23(1):105-114. doi: 10.1111/hae.13111. Epub 2016 Oct 20. Haemophilia. 2017. PMID: 27761962
Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A, Hellmann A, Baglin T, O'Shaugnessy D, Trelinski J, Kuliczkowski K, Kloczko J, Hay C, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Dmoszynska A, et al. Among authors: hay c. Haemophilia. 2011 Mar;17(2):185-90. doi: 10.1111/j.1365-2516.2010.02414.x. Epub 2010 Nov 11. Haemophilia. 2011. PMID: 21070496
Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
Dmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O'Shaughnessy D, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C. Dmoszynska A, et al. Among authors: hay c. Haemophilia. 2011 May;17(3):456-62. doi: 10.1111/j.1365-2516.2010.02446.x. Epub 2011 Mar 4. Haemophilia. 2011. PMID: 21371184 Free PMC article.
429 results